All In Biotech

NDA 204353 · Janssen Pharms

Invokamet

Canagliflozin, Metformin Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Aug 8, 2014

Approved uses

8

Original approval plus efficacy supplements

Registered trials

156

25 Phase 3, 13 recruiting

FAERS reports

1,695

965 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LACTIC ACIDOSIS Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (> 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ] . Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...

What it is approved for

From the label in effect Aug 24, 2026.

INVOKAMET INVOKAMET is a combination of canagliflozin and metformin HCl immediate-release indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. INVOKAMET XR INVOKAMET XR is a combination of canagliflozin and metformin HCl extended-release indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). End-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. Limitations of Use INVOKAMET or INVOKAMET XR are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse...

Mechanism: Canagliflozin SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RT G ), and thereby increases urinary glucose excretion (UGE). Canagliflozin increases the delivery of sodium to the distal tubule by blocking SGLT2-dependent glucose and sodium reabsorption. This is believed to increase tubuloglomerular feedback and reduce intraglomerular...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • INVOKAMET · CANAGLIFLOZIN 150MG; METFORMIN HYDROCHLORIDE 500MG · TABLET, ORAL · Prescription
  • INVOKAMET · CANAGLIFLOZIN 50MG; METFORMIN HYDROCHLORIDE 500MG · TABLET, ORAL · Prescription
  • INVOKAMET · CANAGLIFLOZIN 150MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, ORAL · Prescription
  • INVOKAMET · CANAGLIFLOZIN 50MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Canagliflozin" as an intervention, any sponsor and status, largest first.

All 156 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • osteomyelitis197
  • toe amputation192
  • diabetic ketoacidosis161
  • acute kidney injury101
  • cellulitis92
  • diabetic foot infection84
  • blood glucose increased80
  • gangrene80
  • nausea74
  • off label use73
  • diarrhoea71
  • weight decreased66

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20146
2015292
2016350
2017255
2018350
2019185
202093
202147
202232
202334
202427
202513
202611

Recalls

1 FDA enforcement reports for this application.

  • Oct 19, 2016 · Class III · Terminated

    Labeling: Incorrect or Missing Package Insert - Xarelto prescribing information outserts may be affixed to the exterior of Invokamet bottles in place of the Invokamet prescribing information outsert.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Invokamet (Canagliflozin/Metformin HCl)

2024 spending

$16.4M

Beneficiaries

3,551

15,740 claims

Per beneficiary

$4,612

$9.31 per unit

View as table
YearSpending
2020$41,648,711
2021$30,032,058
2022$27,489,420
2023$22,206,495
2024$16,378,760

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 448 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.